1007882-58-7

Basic information

• Product Name: (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate
• Synonyms: (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate;tert-Butyl (2S)-2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate;tert-Butyl (S)-2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate;-tert-Butyl 2-(1H-imidazol-2-yl);EOS-61042
• CAS NO: 1007882-58-7
• Molecular Formula: C₁₂H₁₉N₃O₂
• Molecular Weight: 237.29816
• Mol File: 1007882-58-7.mol
• Article Data: 50

Chemical Properties

• Boiling Point: 422.6±38.0 °C(Predicted)
• Appearance: /
• Density: 1.170±0.06 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: 13.85±0.10(Predicted)
• CAS DataBase Reference: (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate(CAS DataBase Reference)
• NIST Chemistry Reference: (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate(1007882-58-7)
• EPA Substance Registry System: (S)-tert-butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate(1007882-58-7)

Safety Data

• Hazardous Substances Data: 1007882-58-7(Hazardous Substances Data)

Usage

General Description

(S)-tert-Butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate is a chemical compound with a complex molecular structure. It is a pyrrolidine derivative with a tert-butyl group and an imidazole moiety. (S)-tert-Butyl 2-(1H-imidazol-2-yl)pyrrolidine-1-carboxylate has potential biological and pharmacological activities, and it is commonly used as a building block for the synthesis of various pharmaceuticals and organic compounds. Its specific properties and applications depend on its stereochemistry and functional groups, making it a versatile and valuable chemical in the field of medicinal chemistry and drug discovery.

Upstream product

• 69610-40-8 N-(tert-butoxycarbonyl)-L-prolinol 
• 15761-39-4 1-(tert-butoxycarbonyl)-L-proline 
• 59936-29-7 (S)-N-(tert-butoxycarbonyl)proline methyl ester 
• 1240893-76-8 (S)-2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 147-85-3 L-proline 
• 131543-46-9 Glyoxal 
• 69610-41-9 Boc-L-Pro-H 

Downstream Products

• 1007882-59-8 (S)-2-(4-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1007882-59-8 (S)-2-(5-bromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1252038-18-8 tert-butyl (2S)-2-(1-trityl-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1240893-76-8 (S)-2-(4,5-dibromo-1H-imidazol-2-yl)pyrrolidine-1-carboxylic acid tert-butyl ester 
• 1265681-80-8 C₄₄H₆₈N₆O₆Si₂ 
• 1256547-82-6 2-[(2S)-pyrrolidin-2-yl]-4-[4-(6-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}naphthalen-2-yl)phenyl]-1H-imidazole 
• 1256385-04-2 methyl {(2S)-1-[(2S)-2-{5-[6-(4-{2-[(2S)-1-{(2S)-2-[(methoxycarbonyl)amino]-3-methyl-butanoyl}pyrrolidin-2-yl]-1H-imidazol-4-yl}phenyl)naphthalen-2-yl]-1H-imidazol-2-yl}pyrrolidin-1-yl]-3-methyl-1-oxobutan-2-yl}carbamate 
• 1261071-79-7 tert-butyl (2S)-2-(5-{2-[4-(2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-5-yl)phenyl]quinazolin-6-yl}-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228553-01-2 [(S)-1-((S)-2-{4-[2-(4-{2-[(S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidin-2-yl]-3H-imidazol-4-yl}-phenyl)-quinolin-6-yl]-1H-imidazol-2-yl}-pyrrolidine-1-carbonyl)-2-methyl-propyl]-carbamic acid methyl ester 
• 1261071-84-4 tert-butyl (2S)-2-(5-[6-(4-{2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1H-imidazol-4-yl}phenyl)naphthalen-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1261071-90-2 tert-butyl (2S)-2-(5-[2-(4-{2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)quinoxalin-6-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1261071-93-5 tert-butyl (2S)-2-(5-[6-(4-{2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)quinoxalin-2-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1261072-11-0 tert-butyl (2S)-2-(5-[7-(4-{2-[(2S)-1-(tert-butoxycarbonyl)pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)isoquinolin-3-yl]-1-{[2-(trimethylsilyl)ethoxy]methyl}-1H-imidazol-2-yl)pyrrolidine-1-carboxylate 
• 1228633-28-0 6-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}-2-(4-{2-[(2S)-pyrrolidin-2-yl]-1H-imidazol-5-yl}phenyl)quinoxaline 

Relevant articles and documents

Enantioselective synthesis of an HCV NS5a antagonist

A concise, enantioselective synthesis of the HCV NS5a inhibitor MK-8742 (1) is reported. The features of the synthesis include a highly enantioselective transfer hydrogenation of an NH imine and a dynamic diastereoselective transformation. The synthesis of this complex target requires simple starting materials and nine linear steps for completion.

Discovery of thienoimidazole-based HCV NS5A inhibitors. Part 1: C2-Symmetric inhibitors with diyne and biphenyl linkers

The discovery of C2-symmetric bis-thienoimidazoles HCV NS5A inhibitors is herein reported. Two straightforward approaches to access the requisite diyne and biphenyl linker moieties are described. This study revealed the paramount importance of the aromatic character of the linker to achieve high genotype 1a potency.

INHIBITORS OF HEPATITIS C VIRUS REPLICATION

The present invention relates to compounds of formula (I) that are useful as hepatitis C virus (HCV) NS5A inhibitors, the synthesis of such compounds, and the use of such compounds for inhibiting HCV NS5A activity, for treating or preventing HCV infections and for inhibiting HCV viral replication and/or viral production in a cell-based system.

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.